Current role of diethylstilbestrol in the management of advanced prostate cancer

Pierre Olivier Bosset, Laurence Albiges, Thomas Seisen, Thibault De La Motte Rouge, Véronique Phé, Marc Olivier Bitker, Morgan Rouprêt

    Research output: Contribution to journalReview articlepeer-review

    29 Citations (Scopus)

    Abstract

    The aim of this review was to describe the most recent data from contemporary clinical trials of diethylstilbestrol ( DES) to better determine its current role in advanced prostate cancer treatment as new hormonal therapies emerge. Relevant clinical studies using 1 mg of DES in castrate-resistant prostate cancer (CRPC) were identified from the literature, clinical trial databases, websites and conference abstracts. The efficacy and safety outcomes were summarized. DES in CRPC produced a biological response (change in PSA level) and improved the median survival of patients when used as a second-line hormone therapy after standard androgen deprivation with bicalutamide and LHRH analogues. These findings were for low doses of DES. The 1-mg dose is associated with a reduced toxicity, including fewer thromboembolic and cardiovascular events. Low-dose DES appears to be safe and effective for CRPC before initiating chemotherapy. The cost/efficiency ratio may encourage physicians to consider DES as a therapy option before chemotherapy in non-symptomatic CRPC.

    Original languageEnglish
    Pages (from-to)E826-E829
    JournalBJU International
    Volume110
    Issue number11 C
    DOIs
    Publication statusPublished - 1 Dec 2012

    Keywords

    • Androgen deprivation therapy
    • Diethylstilbestrol
    • Hormone-resistant prostate cancer
    • Low molecular weight heparin
    • PSA
    • Progression

    Cite this